What changed: Nasopharyngeal carcinoma

When this page itself was last checked or edited.

Recurrent or metastatic non-keratinising NPC with cisplatin-gemcitabine; monotherapy after platinum and ≥1 other line

A milestone in how this cancer is treated.

Three-year event-free survival 86 percent with sintilimab added to chemoradiotherapy against 76 percent without (hazard ratio 0.

First FDA approval for nasopharyngeal carcinoma

Recurrent/metastatic nasopharyngeal carcinoma, first line with chemotherapy and later lines

A milestone in how this cancer is treated.

Relapsed/refractory classical Hodgkin lymphoma; later NPC, NSCLC

Induction gemcitabine-cisplatin ×3 then concurrent cisplatin-IMRT (for stage III-IVA); concurrent chemoradiation alone for stage II; adjuvant capecitabine for high-risk (detectable post-RT EBV DNA, N2-3). (NCCN Category 1 (induction GP), ESMO-MCBS A)

Median progression-free survival 9.

PFS HR 0.

A milestone in how this cancer is treated.

Classical Hodgkin lymphoma; subsequently HCC, NSCLC, ESCC (second line 2020, first line with chemotherapy 2021), nasopharyngeal

Classical Hodgkin lymphoma (first); subsequently urothelial, NSCLC, HCC, ESCC, gastric, nasopharyngeal

A milestone in how this cancer is treated.

A milestone in how this cancer is treated.

Late-stage nasopharyngeal carcinoma, with chemotherapy

A milestone in how this cancer is treated.

A milestone in how this cancer is treated.

A milestone in how this cancer is treated.

A milestone in how this cancer is treated.